PV Bulletin

Mandatory Registration for Medical Devices in Switzerland Starting 1 July 2026

Mandatory registration in swissdamed for medical devices and IVDs replaces existing notification procedures with effect from 1 July 2026.

Primary source: Registration fee

PV Impact Brief

Urgency: HighConfidence: high

What changed

The introduction of mandatory registration in swissdamed from 1 July 2026 replaces prior notification procedures for medical devices and IVDs.

Why it matters

This regulatory change enhances market surveillance and ensures that medical devices comply with safety standards before entering the market.

Action needed

Manufacturers must implement processes for device registration in swissdamed before placing devices on the market, with immediate attention needed for vigilance-reportable incidents.

Relevant for
Regulatory Intelligence LeadQPPV
Processes impacted
ICSRCountry Compliance
Owner

Regulatory Intelligence Lead

Review cadence

Review in the next regulatory intelligence cycle.

Policy change details

Document type
Notice
Policy status
effective
Publication date
2026-07-01
Policy change
Mandatory registration in swissdamed for medical devices and IVDs replaces existing notification procedures with effect from 1 July 2026. A transitional period applies until 31 December 2026 for most devices, but registration without a transitional period applies to devices that must be reported to Swissmedic due to serious incidents, FSCAs, or trends.

Key changes

Introduction of mandatory device registration in the swissdamed UDI Devices module; replacement of class I notifications; immediate registration required for vigilance-reportable incidents.

Affected workflows

ICSRCountry Compliance

PV impact

MAHs and manufacturers must use swissdamed for device registration and vigilance-related reporting (incidents, FSCAs, trends) from 1 July 2026 without a transitional period.

View regulator source

Source document details

Exact policy details

Mandatory registration start date
1 July 2026
Applies to: All medical devices, systems, and procedure packs placed on the market in Switzerland.
the introduction of mandatory registration in swissdamed · p. 1 · High · Source
Transitional period end date
31 December 2026
Applies to: Applies to devices, systems, and procedure packs for which sales units are placed on the market after 1 July 2026.
transitional period lasting until 31 December 2026 · p. 1 · High · Source
Registration fee for first device
CHF 200
Applies to: Fee for first UDI-DI registration per year.
A fee of CHF 200 will be charged for the first UDI-DI · p. 1 · High · Source
Registration fee for additional devices
CHF 20
Applies to: Fee for each additional UDI-DI with status 'On the market'.
a flat fee of CHF 20 will be charged for each additional UDI-DI · p. 1 · High · Source
Annual maximum fee
CHF 10,000
Applies to: Cost ceiling per manufacturer per calendar year.
subject to a cost ceiling of CHF 10,000 per calendar year · p. 1 · High · Source
First invoicing date
January 2027
Applies to: For devices registered by 31 December 2026.
The first invoices will be sent from January 2027 · p. 1 · High · Source

Workflow rule impacts

Country ComplianceManufacturer

Manufacturers must adapt their processes to ensure registration before market placement.

Mandatory registration of medical devices in swissdamed

Economic operators must register with Swissmedic before first placing a device on the market · p. 1 · High · Source

Extracted documents

Evidence and confidence

Confidence: highSource updated: Jul 1, 2026

Full briefing

Practical implication

Manufacturers must implement processes for device registration in swissdamed before placing devices on the market, with immediate attention needed for vigilance-reportable incidents.

From 1 July 2026, all medical devices and in vitro diagnostic medical devices must be registered in the swissdamed UDI Devices module. A transitional period allows for registration until 31 December 2026 for most devices, while immediate registration is required for incidents reportable to Swissmedic. The new rules replace class I notifications and introduce a fee structure for registrations. Fees include CHF 200 for the first device and CHF 20 for additional devices, with a maximum of CHF 10,000 charged annually per manufacturer.

What changed: The introduction of mandatory registration in swissdamed from 1 July 2026 replaces prior notification procedures for medical devices and IVDs.

Why it matters: This regulatory change enhances market surveillance and ensures that medical devices comply with safety standards before entering the market.

Practical implication: Manufacturers must implement processes for device registration in swissdamed before placing devices on the market, with immediate attention needed for vigilance-reportable incidents.

View original source

Published from the Firecrawl policy change extraction pipeline.

Related updates for your role

publicFDA · USA · Updated Sep 4, 2026

FDA Grants Accelerated Approval to Etcamah for Advanced Breast Cancer

Urgency: High

Regulatory teams must prepare for updating labeling to include details on the new indication and required diagnostic methods, along with planning for the confirmatory studies mandated by the FDA.

Signal ManagementLabelingRegulatory Intelligence Lead
SOP Impact2 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicMHRA · UK · Updated Sep 4, 2026

Change to the definition of regulated activity with children from 1 September 2026

Urgency: High

Organizations must re-evaluate roles related to children's activities and prepare to request Enhanced DBS checks including access to the Children’s Barred List check starting from 1 September 2026.

Country ComplianceRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicANSM (France) · France · Updated Sep 7, 2026Translated From French

Recall of Gore Viabahn Endoprosthesis with Bioactive Heparin Coating

Urgency: High

Health establishments receiving affected devices must be notified, and protocols established to ensure compliance with the recall.

Signal ManagementQPPV
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: QPPV, Medical Safety Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicANSM (France) · France · Updated Sep 7, 2026Translated From French

Atellica CH Revised C-Reactive Protein (RCRP) Safety Information - Siemens Healthcare Diagnostics

Urgency: High

Laboratories must implement the safety measures as indicated by the action registration number R2625739, effective from the notice date of September 7, 2026.

Signal ManagementQPPV
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: QPPV, Medical Safety Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward